Gilead Says Trodelvy Lung Cancer Trial Didn't Meet Primary Endpoint
22 Janeiro 2024 - 11:17AM
Dow Jones News
By Will Feuer
Gilead Sciences said a Phase 3 trial testing Trodelvy in certain
lung cancer patients failed to improve overall survival, results
that sent shares sharply lower.
Gilead agreed in 2022 to buy Trodelvy-maker Immunomedics for $21
billion.
In the Phase 3 trial, Gilead is evaluating Trodelvy versus
docetaxel in patients with metastatic or advanced non-small cell
lung cancer that had progressed on or after chemotherapy and
checkpoint inhibitor therapy.
Gilead said it did observe a numerical improvement in overall
survival favoring Trodelvy, but that the results didn't meet the
threshold of the primary endpoint.
Gilead said it plans to discuss the trial results with
regulators, and present the data at an upcoming medical
meeting.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
January 22, 2024 09:02 ET (14:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Gilead Sciences (NASDAQ:GILD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
